Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
Fabio Puglisi(University of Udine), Lucia Del Mastro(Ospedale Policlinico San Martino), Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Claudia Bighin(Azienda Ospedaliera S.Maria), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Filippo Montemurro(Roche (Switzerland)), Andrea Ardizzoni(Azienda Ospedaliero-Universitaria Careggi), Teresa Gamucci, Giancarlo Bisagni, Lorenzo Gerratana(National Cancer Institute), Mario Giuliano(Regione Campania), Anna Turletti(Ospedale Martini), Sabino De Placido, Stefania Russo(National Center for Oncological Hadrontherapy), Luca Boni(Ospedale Policlinico San Martino), Matteo Lambertini(Ospedale Policlinico San Martino), Giuseppe Colantuoni(Azienda Ospedaliera S.Giuseppe Moscati), Marcello Ceppi(Ospedale Policlinico San Martino), Adriano Gravina(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), F. Cognetti(Sapienza University of Rome), Antonio Durando(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino)
Cited by 9
Related Papers
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830